Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Premium

Strides Up 12% on FDA Approval, Portfolio Gains

This is a Capital Mind Premium post, sent on April 26, 2014.

Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor Strides’ Bangalore oral dosage facility. It has gone up 12 to Rs. 526.

Note: Ignore the fall (it’s the dividend adjustment).

We have purchased Strides in the Capital Mind Premium portfolio in December,

Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial